Effects of TP53 Mutations and miRs on Immune Responses in the Tumor Microenvironment Important in Pancreatic Cancer Progression
Open accessThe DOI matches its Crossref record; 205 of the 210 references it cites were found in a registry or an index.
Abstract
Approximately 90% of pancreatic cancers are pancreatic ductal adenocarcinomas (PDAC). PDAC is the fourth leading cause of cancer death world-wide. Therapies for PDAC are largely ineffective due to the dense desmoplastic tumor microenvironment which prevents chemotherapeutic drugs and small molecule inhibitors from exerting effective anti-cancer effects. In this review, we will discuss the roles of TP53 and miRs on the PDAC tumor microenvironment and how loss of the normal functions of TP53 promote tumor progression. The TP53 gene is mutated in approximately 50% of pancreatic cancers. Often, these TP53 mutations are point mutations which confer additional functions for the TP53 proteins. These are called gain of function (GOF) mutations (mut). Another class of TP53 mutations are deletions which result in loss of the TP53 protein; these are referred to TP53-null mutations. We have organized this review into various components/properties of the PDAC microenvironment and how they may be altered in the presence of mutant TP53 and loss of certain miR expression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“TP53 mutations, found in 50–90% of pancreatic ductal adenocarcinomas, significantly affect carcinogenesis, prognosis and treatment response [17,21,34,35].”
From Significance of TP53, CDKN2A, SMAD4 and KRAS in Pancreatic Cancer (2024) · cites this paper as [34]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“These mutations, particularly gain-of-function (GOF) variants, alter the tumor microenvironment, promoting proliferation and chemotherapy resistance [34,36].”
From Significance of TP53, CDKN2A, SMAD4 and KRAS in Pancreatic Cancer (2024) · cites this paper as [34]
The cited source says what the claim attributes to it.
In the citing paper
“TP53’s multifaceted role extends to metabolic regulation, shaping the hostile PDAC microenvironment by influencing metabolic reprogramming, autophagy and ferroptosis [34].”
From Significance of TP53, CDKN2A, SMAD4 and KRAS in Pancreatic Cancer (2024) · cites this paper as [34]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Items 201–205 of 205
Renaldi, K., Marcellus Simadibrata, K., Rahadiani, N., Handjari, D. R., William, A., Sinuraya, F. A. G., & Makmun, D. (2021) · The Turkish Journal of Gastroenterology · doi:10.5152/tjg.2021.211106 · Cited by 8 · cited 1×
“The elevation in expression is often mediated by mutations in KRAS, epithelial growth factor receptor (EGFR), phosphatidylinositol 3-kinase (PI3K, PIK3CA) and TP53 [69].”
BackgroundAbrams, S. L., Akula, S. M., Martelli, A. M., Cocco, L., Ratti, S., Libra, M., Candido, S., Montalto, G., Cervello, M., Gizak, A., et al. (2021) · Advances in Biological Regulation · doi:10.1016/j.jbior.2020.100780 · Cited by 7 · cited 1×
“Introduction of a WT-TP53 gene into PDAC cells which have either GOF mut-TP53 or were TP53-null will increase their sensitivity to many chemotherapeutic drugs, signal transduction inhibitors and natural products [184,185].”
BackgroundSelf-citationCáceres, M., Quesada, R., Iglesias, M., Real, F. X., Villamonte, M., de Villarreal, J. M., Pérez, M., Andaluz, A., Moll, X., BERJANO, E. J., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-74947-4 · Cited by 6 · cited 1×
“Genetic studies indicated that in the absence of NUPR1 in a mouse model, mut-KRAS (G12D) did not result in the development of PanIns, which is a precursor of the high lethal PDAC [155,156].”
BackgroundP53 mediates the protective effects of metformin in inflamed lung endothelial cells
Kubra, K., Uddin, M. A., Akhter, M. S., Leo, A. J., Siejka, A., & Barabutis, N. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.108367 · Cited by 6 · cited 1×
“In some experiment systems, metformin can interact with TP53 and have protective effects on lung endothelial cells [190].”
Background[Nuclear protein 1 knockdown inhibits proliferation and migration of HepG2 cells].
Huang, H., Zhang, Y., Wang, X., Zhou, X., Li, S., Wang, M., & Ren, J. (2015) · PubMed · Cited by 3
Cited by
Significance of TP53, CDKN2A, SMAD4 and KRAS in Pancreatic Cancer
Stefanoudakis, D., Frountzas, M., Schizas, D., Michalopoulos, N. V., Drakaki, A., & Toutouzas, K. G. (2024) · Current Issues in Molecular Biology · doi:10.3390/cimb46040177 · Cited by 110
“…in fl uencing mRNA degradation mechanisms [36]. variants, alter tumor microenvironment, promoting proliferation and chemotherapy resistance [34, Cases with TP53 mutations often co-occur These mutations, particularly gain-of-function (GOF) variants, alter the tumor microenvironment,…”
BackgroundTP53 Mutation-Mediated Immune Evasion in Cancer: Mechanisms and Therapeutic Implications
Wang, C., Tan, J. Y. M., Chitkara, N., & Bhatt, S. (2024) · Cancers · doi:10.3390/cancers16173069 · Cited by 68
“The cGAS-STING pathway is a critical mechanism of the innate immune system that detects cytosolic DNA, a signal often associated with viral infections or cellular damage [14,61].”
BackgroundAkter, K., Gul, K., & Mumtaz, S. (2025) · Current Issues in Molecular Biology · doi:10.3390/cimb47090716 · Cited by 74
“Extensive research indicates that nonfunctional mutated p53 sig-Curr nificantly contributes to tumor initiation and progression, correlating with poor clinical outcomes, reduced survival rates, unfavorable prognosis, and chemotherapy resistance in oncology patients [80–82].”
Zhang, C.-Y., Liu, S., & Yang, M. J. (2022) · World Journal of Gastroenterology · doi:10.3748/wjg.v28.i48.6827 · Cited by 40
TP53 to mediate immune escape in tumor microenvironment: an overview of the research progress
Zhu, K., Su, F., Yang, J., Xiao, R., Wu, R.-Y., Cao, M.-Y., Ling, X., & Zhang, T. (2024) · Molecular Biology Reports · doi:10.1007/s11033-023-09097-7 · Cited by 41
Metadata
- Authors
- McCubrey, J. A., Yang, L. V., Abrams, S. L., Steelman, L. S., Follo, M. Y., Cocco, L., Ratti, S., Martelli, A. M., Augello, G., & Cervello, M.
- Affiliations
- East Carolina University (US)
- University of Bologna (IT)
- Institute for Biomedical Research and Innovation (IT)
- Corresponding author
- McCubrey, James A.
- ORCID
- Venue
- Cells
- Publisher
- MDPI AG
- Published
- 2022-07-09
- Volume
- 11
- Issue
- 14
- Pages
- 2155
- ISSN
- 2073-4409 (ISSN-L)
- PMC
- PMC9318640
- OpenAlex
- W4285014119
- Cited by
- 49
- References
- 210
- Citations by year
- 2026: 5 · 2025: 20 · 2024: 17 · 2023: 3 · 2022: 4
- FWCI
- 1.34
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Cells (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- East Carolina University Grant (#111104, #111110-668715-0000)
- Fondazione del Monte di Bologna e Ravenna Research grant (#111104, #111110-668715-0000)
- Topics
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › MicroRNA in disease regulation
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Keywords
- TP53 mutation, microRNA, pancreatic ductal adenocarcinoma, tumor microenvironment, desmoplasia, immune response, tumor progression, gain-of-function mutations, chemoresistance
- MeSH terms
- Humans, Immunity, Mutation, Pancreatic Neoplasms, Tumor Suppressor Protein p53, Carcinoma, Pancreatic Ductal, MicroRNAs, Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.